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Abstract
Background: Evaluating women with symptoms suggestive of coronary artery disease (CAD) remains chal-
lenging. A blood-based precision medicine test yielding an age/sex/gene expression score (ASGES) has shown
clinical validity in the diagnosis of obstructive CAD. We assessed the effect of the ASGES on the management
of women with suspected obstructive CAD in a community-based registry.
Materials and Methods: The prospective PRESET (A Registry to Evaluate Patterns of Care Associated with the
Use of Corus CAD in Real World Clinical Care Settings) Registry (NCT01677156) enrolled 566 patients
presenting with symptoms suggestive of stable obstructive CAD from 21 United States primary care practices
from 2012 to 2014. Demographics, clinical characteristics, and referrals to cardiology or further functional
and/or anatomical cardiac studies after ASGES testing were collected for this subgroup analysis of women from
the PRESET Registry. Patients were followed for 1-year post-ASGES testing.
Results: This study cohort included 288 women with a median age 57 years. The median body mass index was
29.2, with hyperlipidemia and hypertension present in 48% and 43% of patients, respectively. Median ASGES
was 8.5 (range 1–40), with 218 (76%) patients having low (£15) ASGES. Clinicians referred 9% (20/218) low
ASGES versus 44% (31/70) elevated ASGES women for further cardiac evaluation (odds ratio 0.14, p< 0.0001,
adjusted for patient demographics and clinical covariates). Across the score range, higher ASGES were as-
sociated with a higher likelihood of posttest cardiac referral. At 1-year follow-up, low ASGES women expe-
rienced fewer major adverse cardiac events than elevated ASGES women (1.3% vs. 4.2% respectively,
p= 0.16).
Conclusions: Incorporation of ASGES into the diagnostic workup demonstrated clinical utility by helping
clinicians identify women less likely to benefit from further cardiac evaluation.
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Introduction
Sex-specific differences in cardiovascular disease con-tribute to unique diagnostic challenges in the evaluation
of women with suspected coronary artery disease (CAD).
Women with suspected CAD are more likely than men to
present with atypical symptoms, and noninvasive diagnostic
testing—recommended by the American Heart Association
(AHA)/American College of Cardiology (ACC)—is more
likely to yield a falsely negative result in women compared
with men.1 The workup for suspected CAD in women is also
associated with errors of commission—in the form of un-
necessary testing—as well as omission—with undertesting in
appropriate patients—both of which contribute to suboptimal
care.2–5
Current AHA/ACC guidelines recommend noninvasive
exercise electrocardiogram (ECG) with or without imaging
for diagnostic evaluation. However, advancements in preci-
sion medicine hold significant promise for improving care
and health outcomes among women presenting with typical
and atypical angina symptoms.6, 7 A blood-based age/sex/gene
expression score (ASGES) for the evaluation of obstructive
CAD incorporates several key features of precision medi-
cine—including integration of age- and sex-specific patient
characteristics as well as molecular genomics and compatibility
with web portal/electronic health records—thereby providing
physicians with additional data to assess patients with symp-
toms suggestive of obstructive CAD. The ASGES test, ranging
from a score of 1–40, with higher scores associated with an
increased current likelihood of obstructive CAD, has been
validated in multiple studies involving nondiabetic patients
referred for invasive coronary angiography (ICA) and myo-
cardial perfusion imaging (MPI) and has been shown to have a
96% negative predictive value in a combined cohort of men
and women in the COMPASS (Coronary Obstruction Detec-
tion by Molecular Personalized Gene Expression) study.8–10
When compared to MPI, the ASGES independently im-
proved the diagnosis evaluation of obstructive CAD in both
men and women, whereas MPI was a less reliable test in
women, with rates of angiographically proven obstructive
CAD being similar among women with positive and nega-
tive MPI (22% vs. 18.5%).8 Furthermore, in the recent Na-
tional Heart, Lung, and Blood Institute-sponsored PROMISE
(Prospective Multicenter Imaging Study for Evaluation of
Chest Pain) substudy, the ASGES test was performed in
2,380 nondiabetic patients presenting with symptoms sug-
gestive of obstructive CAD. In this study, higher ASGES
scores were associated with higher current likelihood of ob-
structive CAD as well as higher likelihood of the composite
endpoint of death, myocardial infarction (MI), unstable an-
gina, or revascularization procedures at 2-year follow-up.11
Furthermore, a recent 2017 AHA Scientific Statement on the
Expressed Genome highlighted the ASGES and its clinical
value in the evaluation of patients with suspected obstructive
CAD.12
The ASGES test is the only sex-specific diagnostic tests
designed to risk stratify patients with symptoms suggestive of
obstructive CAD. In this study, we examined all women in
the community-based PRESET (A Registry to Evaluate
Patterns of Care Associated with the Use of Corus CAD in
Real World Clinical Care Settings; PRESET Registry,
NCT01677156) Registry to determine the clinical utility of
the ASGES, based on its potential effects on medical decision-
making and referrals to cardiology or advanced cardiac test-
ing.13 The PRESET Registry differs from the previously
published pooled cohort of women from REGISTRY I and
IMPACT studies.14 The IMPACT-PCP (Investigation of a
Molecular Personalized Coronary Gene Expression Test on
Primary Care Practice Pattern) study incorporated a rigorous
clinical trial design, including more restrictive entry criteria
and predefined follow-up time points. In contrast, PRESET
used a registry-type design to measure clinical effectiveness
and more accurately reflects real-world decision-making and
outcomes. For these same reasons, it is possible that the results
in this PRESET subgroup are more generalizable.
Materials and Methods
Study tools
The age/sex/gene expression blood test (Corus CAD,
CardioDx, Inc., Redwood City, CA) is intended for use in
stable patients with a history of chest pain or suspected an-
ginal equivalents. The ASGES test is not intended for use in
patients with diabetes, systemic infectious or systemic in-
flammatory conditions, or who are currently taking steroids,
immunosuppressive agents, or chemotherapeutic agents.15
The ASGES test is a commercially available, quantitative
test measuring expression levels of 23 genes from a periph-
eral blood sample. These genes are selectively expressed in
multiple types of circulating cells, including neutrophils,
natural killer cells, as well as B and T lymphocytes. These
cells play supporting roles in both adaptive and innate im-
mune responses in atherosclerosis.16 Whole blood samples
were collected in PAXgene Blood RNA Tube (PreAnalytiX,
Hombrechtikon, Switzerland) and were processed as previ-
ously described.15
Previously validated sex-specific algorithms with age and
gene expression inputs are used to generate the ASGES,
ranging in value from 1 to 40.15 Each value is associated with
the current likelihood of obstructive CAD: higher ASGES are
associated with higher current likelihood of obstructive
CAD, which is defined as at least one atherosclerotic plaque
causing ‡50% luminal diameter stenosis in a major coronary
artery (‡1.5 mm lumen diameter), and has been correlated
with invasive quantitative coronary angiography or core
laboratory coronary computed tomography angiography
(CCTA) (‡2.0 mm).17 Patients in the ASGES validation
studies were stratified into low ASGES (£15) (estimated
probability of obstructive CAD £8%) and elevated ASGES
(>15) (estimated probability of obstructive CAD >8%) sub-
groups for further analysis. A low ASGES score (£15) was
found to have a 96% negative predictive value in a combined
population of men and women (N= 431) for determining a
patient’s current likelihood of having obstructive CAD and is
associated with low rates (0.5%) of major adverse cardiac
event (MACE) or revascularization during 6 month follow-
up in the COMPASS study.10
Study design
The prospective PRESET Registry enrolled stable, non-
diabetic adult patients without a history of CAD from 21
United States primary care practices from August 2012 to
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August 2014. Quorum Review, Inc. granted Institutional
Review Board (IRB) approval, and all enrolled patients
signed an IRB-approved informed consent form. Clinicians
and their office staffs at each of the primary care sites were
educated and trained on the use and interpretation of the
ASGES through a standardized, in-service program. Clin-
icians solely determined whether their patients met the in-
tended use criterion and received ASGES testing.
The study group comprised symptomatic patients who
presented to primary care clinicians for the evaluation of
suspected obstructive CAD and underwent ASGES testing.
Patients were classified as having typical angina symptoms,
such as substernal chest discomfort, aggravation with exertion,
and alleviation with rest as well as dyspnea, or atypical angina
symptoms, such as, palpitations, malaise, and fatigue. At
baseline, data regarding patient demographics and medical
history were recorded. On follow-up, ASGES results, referrals
to cardiology or advanced cardiac testing, and major adverse
cardiac outcomes were measured. A total of 566 patients were
enrolled in the PRESET Registry: this predefined analysis
focused on the 288 (51%) subgroup of women patients.
Study outcomes
The primary objective of the study was to evaluate the
ASGES score and its effects on medical decision-making—
specifically, referrals to cardiology or further cardiac testing—
in a community-based cardiovascular patient registry at 45 day
follow-up. Further cardiac testing was defined as exercise
treadmill testing (ETT), exercise stress echocardiogram
(ECHO), MPI, CCTA, or ICA. Follow-up of registry patients
was conducted at 1-year by chart review to assess the incidence
of MACE, defined as a composite of stroke/transient ischemic
attack (TIA), MI, and cardiac-related death.
Statistical analyses
Descriptive statistics for univariate analyses, including
means and standard deviations, counts and percentages, and
counts of missing data records, were calculated for continu-
ous and categorical variables, as appropriate. Tests for sta-
tistical association between cardiac referral and ASGES
classification as a binary variable (predefined as low score
[<15] and elevated score [>15]) as well as a continuous
variable from 1 to 40 were performed using logistic regres-
sion, with and without adjustment for participant character-
istics and clinical covariates (smoking, race/ethnicity, body
mass index [BMI], hypertension, and hyperlipidemia). Odds
ratios (ORs), 95% confidence intervals, and p-values were
used to assess statistical significance of the results. All ana-
lyses were performed using R (version 3.0.2).18
Results
The cohort of 288 women had a median age of 57 years
(interquartile range 44–68) and was predominantly white
(81%). The median BMI was 29.2, 34% were recent smokers,
and hyperlipidemia and hypertension were present in 48%
and 43% of patients, respectively. Approximately one-third
(35%) had typical angina symptoms at the time of presenta-
tion. The median ASGES was 8.5 (range, 1–40) (Table 1).
After ASGES testing, 218 patients (76%) had low scores.
Clinicians referred 20/218 (9%) patients with low scores
versus 31/70 (44%) patients with elevated scores to cardiology
or advanced cardiac testing (ETT, ECHO, MPI, CCTA, and
ICA) (OR 0.13, p£ 0.0001 on univariate analysis) (Table 2). In
multivariate analyses adjusting for clinical covariates BMI,
smoking status, hypertension, and hyperlipidemia, the asso-
ciation between low ASGES and low rate of referral persisted
(OR 0.14, p< 0.0001), while other demographic factors were
not associated with cardiac referral (Table 3). Analysis of
the ASGES as a continuous variable showed that the rate of
cardiac referral increased proportionally with the score, with
referral rates of 9% (20/218), 40% (21/52), and 55% (10/18)
among low- (ASGES 1–15), intermediate- (ASGES 16–27),
and high-score (ASGES 28–40) patients, respectively ( p<
0.0001) (Fig. 1). For every five-point increase in ASGES, the
adjusted OR of referral increased by 1.54-fold in the multi-
variate model ( p< 0.0001).
There were six patients (6/288, 2.1%) with MACE within
the 1-year follow-up period. There were four women (4/288,
1.4%), who experienced a stroke/TIA, and two women
Table 1. Clinical and Demographic
Characteristics of Women in the PRESET
Registry (N= 288)
Age Median 57 (25–96)
Race
White 234 (81%)
Black 44 (15%)
Asian 5 (2%)
American Indian
or Alaska Native
1 (0%)
Other 4 (1%)
BMI (n= 285) Median 29.2 (15.3–67.29)
Systolic BP (n = 286) Mean 128.5 (–16.86)
Diastolic BP (n = 286) Mean 75.67 (–11.49)
Smoker status
Current 47 (16%)
Quit within last month 1 (0%)
Quit more than 1 month ago 51 (18%)
Never 189 (66%)
Anginal symptoms
Typical 102 (35%)
Atypical 186 (65%)
Medical history
Hypertension 124 (43%)
Hyperlipidemia 138 (48%)
Carotid artery disease 5 (2%)
Peripheral artery disease 1 (0%)
Liver disease 1 (0%)
Cancer 10 (3%)
Postmenopausal 184 (64%)
Systemic inflammatory 2 (1%)
Arrhythmia 8 (3%)
Respiratory conditions 31 (11%)
Autoimmune or
Inflammatory
8 (3%)
ASGES median 8.5 (range 1–40)
PRESET, A Registry to Evaluate Patterns of Care Associated
with the Use of Corus CAD in Real-World Clinical Care Settings;
BMI, body mass index; BP, blood pressure; ASGES, age/sex/gene
expression score.
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(2/288, 0.7%), who died. Major adverse cardiac outcomes
occurred in three patients (3/218, 1.3%) with low ASGES
and three patients (3/70, 4.2%) with elevated ASGES
( p = 0.16).
Discussion
A major challenge faced by primary care providers is the
evaluation of typical and atypical chest pain in women, be-
cause conventional diagnostic approaches are limited in their
ability to rule-out or rule-in CAD in the outpatient setting.
In this prospective, community-based registry study of non-
diabetic women evaluated for suspected stable CAD, the
addition of the ASGES test, derived from a sex-specific al-
gorithm with age and gene expression inputs, demonstrated
clinical utility through its significant association with clini-
cal decision-making. Women with low ASGES had an 86%
decreased odds of referral for further cardiac evaluation
compared with women with elevated ASGES. In addition,
proportionally higher rates of referral among higher ASGES
patients were noted across the ASGES range of 1–40. One-
year follow-up data in this cohort support the safety of this
diagnostic approach among patients with suspected ob-
structive CAD. Thus, an ASGES-guided strategy may reduce
unnecessary cardiac stress testing and CCTA among women.
The purpose of the ASGES is not to supplant a patient’s
history, but rather to aid in the diagnostic evaluation, similar
to the manner that functional/anatomical cardiac testing is
used. Based on Diamond–Forrester estimates and the prev-
alence of symptoms in PRESET Registry, most women in
this study likely had intermediate pretest probability of CAD,
which corresponds to a probability of CAD of 10%–90%,
according to AHA guidelines.19,20 We did not estimate Fra-
mingham risk scores because the ASGES informs the current
likelihood of obstructive CAD, in contrast to Framingham
scores, which provide information about prognosis.
Current AHA guidelines recommend that patients with
intermediate pretest probability of CAD be referred for car-
diac stress testing or CCTA, which routinely requires patients
to take substantial time away from work or other activities,
and frequently also requires radiation and contrast expo-
sure.21,22 However, *75% of the patients in this study had
low ASGES, classifying them as patients with low current
likelihood of obstructive CAD as well as a low 1.3% MACE
rate at 1-year follow-up. One-year MACE rate in women with
low ASGES in this study was similar to the annual mortality
rate after a negative MPI or CCTA as noted in the PROMISE
substudy. In addition, the PROMISE substudy demonstrated
that patients with an ASGES £15 had a composite MACE
rate similar to those with negative noninvasive test results
during 2-year follow-up (3.2% vs. 2.6%, p = 0.29).11
In addition to the prospect of avoiding unnecessary cardiac
testing for low-risk patients, women evaluated with the
Table 2. Referral to Cardiology or Advanced Cardiovascular Testing
(ETT, ECHO, MPI, CCTA, and ICA) (Univariate Analysis)
Referred to
cardiologist or
further cardiac
testing
Not referred
to cardiologist
or further
cardiac testing OR (95% CI) p-Value
ASGES £15 (n= 218) 20 (9%) 198 (91%) 0.13 (0.06–0.26) <0.0001
ASGES >15 (n= 70) 31 (44%) 39 (56%)
ETT, exercise treadmill testing; ECHO, exercise stress echocardiogram; MPI, myocardial perfusion imaging; CCTA, coronary computed
tomography angiogram; ICA, invasive coronary angiography; CI, confidence interval; OR, odds ratio.
Table 3. Referral to Cardiology or Advanced
Cardiovascular Testing (ETT, ECHO, MPI, CCTA,
and ICA) (Multivariate Analysis)
Characteristic OR 95% CI p-Value
Low ASGES score (£15) 0.14 0.06 0.29 <0.0001
Current smoker 0.69 0.22 1.85 0.495
Hypertension 1.37 0.66 2.87 0.396
Dyslipidemia 1.09 0.51 2.32 0.816
White race 0.57 0.24 1.41 0.207
BMI ‡30 1.64 0.82 3.36 0.163
FIG. 1. Relationship between ASGES group and per-
centage of referral to cardiology or advanced cardiac testing.
ASGES, age/sex/gene expression score.
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ASGES are also more likely to receive an accurate diagno-
sis. Comparative data from the PREDICT (Personalized
Risk Evaluation and Diagnosis in the Coronary Tree) and
COMPASS studies have shown that the ASGES outperforms
Diamond–Forrester as well as Morise scores in the evaluation
of current likelihood of obstructive CAD among symptom-
atic patients.
In the PREDICT study, receiver-operating characteristics
(ROC) analysis for prediction of obstructive CAD showed a
higher area under the curve (AUC) for the ASGES and
Diamond–Forrester risk score combination than for the
Diamond–Forrester risk score alone (AUC, 0.72 vs. 0.66;
p = 0.003).9 In the COMPASS study, a similar ROC analy-
sis yielded values of 0.79, 0.67, and 0.69 for the ASGES,
Morise, and Diamond–Forrester scores, respectively ( p <
0.001). Furthermore, in the COMPASS study, the ASGES
(ROC 0.79) outperformed MPI (ROC 0.63) in ROC analyses
for obstructive CAD discrimination.10 These findings em-
phasize the role of ASGES as a tool to aid in the diagnostic
evaluation of women with suspected CAD.
Improving the efficiency of the diagnostic process for
suspected obstructive CAD is of particular importance in
women.23 Patients invest a significant amount of resources in
the form of time and out-of-pocket expenses during an
evaluation for CAD, and opportunity costs of these invest-
ments include time away from work and other productive or
valued activities. Patients also frequently bear risks associ-
ated with exposure to radiation and contrast agents during
their evaluation.24, 25 While the opportunity costs of evalu-
ation are common to both men and women, the risks asso-
ciated with radiation and contrast agents are heightened in
women, due to radiological susceptibility of breast tissue and
the risk of contrast-induced injury to the kidney and thy-
roid.24–27 From a societal perspective, the ASGES has been
shown to be cost-effective and may reduce overall health care
expenditures.28,29, 30
In this cohort, we also observed that many women with
elevated scores (56%) were not referred for further cardiac
evaluation. This finding may be attributable to multiple
causes. For example, patients may have preferred to avoid
subsequent testing, physicians may have recommended med-
ical management with initiation or titration of preventive
medications such as statins or beta blockers, or patients’
symptoms may have resolved. A recent meta-analysis simi-
larly demonstrated analogous variability in referral to cardiac
catheterization after normal or abnormal cardiac stress test
results.31 In addition, we also observed that 9% of women
with low scores were referred for further cardiac evaluation.
This finding may be attributable to multiple causes. For ex-
ample, patients may have preferred to have subsequent test-
ing, and/or physicians may have been concerned about the
severity of the patient’s symptoms despite the low score.
Importantly, the test is not designed to be prescriptive in
nature. Rather, we advise that clinicians use the ASGES—in
the context of other clinical information—to determine the
current likelihood of CAD and whether further cardiac testing
is necessary.
Similar variability was demonstrated in a large registry of
patients referred for MPI, positron emission tomography, or
CCTA.32 Furthermore, the referral rates in low ASGES wo-
men we now report are higher than the referral rate reported
from the combined cohort of women from the REGISTRY I
and IMPACT-PCP studies, two other clinical utility studies
on the ASGES.14 We are uncertain of the reasons for these
differences, but this finding may be due to the fact that phy-
sicians in this PRESET Registry practiced in a larger number
(21 vs. 8) of United States primary care practices and were less
experienced with the use of the ASGES compared with phy-
sicians in the IMPACT-PCP or REGISTRY-1 studies.
Our study has several limitations. The absence of a control
group in the PRESET Registry limits inferences about overall
effectiveness compared with usual care, although our logistic
regression analyses demonstrated a relationship between low
ASGES and decreased cardiac referrals that is independent
of several demographic and clinical characteristics. None-
theless, these data from a real-world registry do not allow us
to directly infer the incremental impact of ASGES on
decision-making, relative to usual care. Second, because
the focus of this study was clinical decision-making, we did
not perform additional validation tests as part of the study
protocol. Furthermore, we were underpowered to statisti-
cally assess MACE rates. A low MACE rate has been ob-
served recently in other studies, such as the NIH-sponsored
PROMISE Trial (NCT01174550), where the MACE rate
(including procedural complications) among 10,003 patients
referred for advanced cardiac testing was 3% at 2-year
follow-up.33
Contemporary studies may require substantially larger
study populations to robustly evaluate this outcome. How-
ever, the clinical validation studies PREDICT, COMPASS,
and PROMISE substudy have previously reported robust test
performance along with safety and long-term follow-up data.
Of note, these clinical validation studies did not consider the
contribution of microvascular disease as a cause of patients’
symptoms, which may occur without obstructive CAD and is
associated with worse outcomes among women compared to
men.34, 35 Third, although baseline characteristics of patients
in the PRESET Registry are comparable to other cohorts of
patients with suspected CAD, the PRESET population may
differ in other meaningful ways that may limit generaliz-
ability. Of note, the ASGES has been shown to have similar
diagnostic characteristics among Caucasian and non-
Caucasian populations. Specifically, in an analysis of the
PREDICT and COMPASS trials, we performed a subanalysis
that included 138 non-Caucasian and 1,364 Caucasian pa-
tients. This subanalysis demonstrated very similar ASGES
performance between these two populations (AUCs = 0.72
vs. 0.70, respectively).36
Fourth, in this real-world setting, we observed that *4%
of patients had contraindications for use of the ASGES test
(3% autoimmune or inflammatory disease and 1% systemic
inflammatory disease). In addition, the results of this study
cannot be generalized to patients for whom the ASGES has
not been validated, such as patients with diabetes. During the
development of the ASGES, it was discovered that distinct
genes are dysregulated in diabetic patients with obstructive
CAD versus without nondiabetic patients with obstructive
CAD.15 This finding may be due to differences in patho-
physiology or may be related to diabetes-specific medications.
A subsequent study also showed that genetic polymorphisms
can have independent effects on CAD likelihood, specifically
in diabetic patients.37
Finally, the results here represent a subgroup analysis of
women from the larger PRESET Registry.38 Such subgroup
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analyses in women have been encouraged by several ini-
tiatives, including GoRedforWomen,39 Women’s Heart
Alliance,40 and CardioSmart (ACC) Women and Heart Dis-
ease.41 The work of Blum and Blum and McSweeney et al.,
among others, have provided the rationale for exploring sex
differences in the evaluation of men and women with sus-
pected obstructive CAD.42, 43 Furthermore, because of the
challenges and risks associated with workup of women sus-
pected of having obstructive CAD, the use of subgroup an-
alyses in this setting may be justified: limiting subgroup
analyses to those most likely to demonstrate greater benefit
or harm, combined with formal testing and reporting of the
subgroup results, may provide an opportunity to support
safer, more cost-effective care.44
Conclusions
A major challenge faced by primary care providers is the
accurate and efficient evaluation of chest pain and related
symptoms in women. In this large community-based regis-
try, the ASGES demonstrated clinical utility among women
evaluated for suspected obstructive CAD. Low ASGES was
associated with lower rates of subsequent cardiac referral as
well as low MACE rates and identified a population of wo-
men who were less likely to benefit from further cardiac
evaluation.
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